Viracta Therapeutics Inc (NASDAQ:VIRX)
| 1.38 Delayed Data As of 3:59pm ET |  -0.02 / -1.43%Today’s Change | 1.21 Today|||52-Week Range 5.75 | -5.48% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $59.5M |
Company Description
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Contact Information
Viracta Therapeutics, Inc. 2533 South Coast Highway 101 Cardiff California 92007 |
Employees
Shareholders
| Mutual fund holders | 7.60% |
| Other institutional | 25.63% |
| Individual stakeholders | 2.31% |
Top Executives
| Mark A. Rothera | President, Chief Executive Officer & Director |
| Daniel R. Chevallard | Secretary, Chief Operating & Financial Officer |
| Lisa Rojkjaer | Chief Medical Officer |
| Ayman El-Guindy | Chief Scientific Officer |
| Patric Nelson | Senior VP-Business Development & Strategy |
